CoChat
Sign Up
Cited by 551Ovarian function and disordersGenetic and Kidney Cyst DiseasesReproductive Biology and Fertility

The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.

Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society

Dewailly, D., Lujan, M. E., Carmina, E., Cedars, M. I., Laven, J., Norman, R. J., Escobar-Morreale, H. F.·2014·Human Reproduction Update
DOI 10.1093/humupd/dmt061
Open this paper in CoChat — free account

Abstract

BACKGROUND The diagnosis of polycystic ovary syndrome (PCOS) relies on clinical, biological and morphological criteria. With the advent of ultrasonography, follicle excess has become the main aspect of polycystic ovarian morphology (PCOM). Since 2003, most investigators have used a threshold of 12 follicles (measuring 2-9 mm in diameter) per whole ovary, but that now seems obsolete. An increase in ovarian volume (OV) and/or area may also be considered accurate markers of PCOM, yet their utility compared with follicle excess remains unclear. METHODS Published peer-reviewed medical literature about PCOM was searched using PubMed.gov online facilities and was submitted to critical assessment by a panel of experts. Studies reporting antral follicle counts (AFC) or follicle number per ovary (FNPO) using transvaginal ultrasonography in healthy women of reproductive age were also included. Only studies that reported the mean or median AFC or FNPO of follicles measuring 2-9 mm, 2-10 mm or <10 mm in diameter, or visualized all follicles, were included. RESULTS Studies addressing women recruited from the general population and studies comparing control and PCOS populations with appropriate statistics were convergent towards setting the threshold for increased FNPO at ≥25 follicles, in women aged 18-35 years. These studies suggested maintaining the threshold for increased OV at ≥10 ml. Critical analysis of the literature showed that OV had less diagnostic potential for PCOM compared with FNPO. The review did not identify any additional diagnostic advantage for other ultrasound metrics such as specific measurements of ovarian stroma or blood flow. Even though serum concentrations of anti-Müllerian hormone (AMH) showed a diagnostic performance for PCOM that was equal to or better than that of FNPO in some series, the accuracy and reproducibility issues of currently available AMH assays preclude the establishment of a threshold value for its use as a surrogate marker of PCOM. PCOM does not associate with significant consequences for health in the absence of other symptoms of PCOS but, because of the use of inconsistent definitions of PCOM among studies, this question cannot be answered with absolute certainty. CONCLUSIONS The Task Force recommends using FNPO for the definition of PCOM setting the threshold at ≥25, but only when using newer technology that affords maximal resolution of ovarian follicles (i.e. transducer frequency ≥8 MHz). If such technology is not available, we recommend using OV rather than FNPO for the diagnosis of PCOM for routine daily practice but not for research studies that require the precise full characterization of patients. The Task Force recognizes the still unmet need for standardization of the follicle counting technique and the need for regularly updating the thresholds used to define follicle excess, particularly in diverse populations. Serum AMH concentration generated great expectations as a surrogate marker for the follicle excess of PCOM, but full standardization of AMH assays is needed before they can be routinely used for clinical practice and research. Finally, the finding of PCOM in ovulatory women not showing clinical or biochemical androgen excess may be inconsequential, even though some studies suggest that isolated PCOM may represent the milder end of the PCOS spectrum.

Overview

Integrity signals

Registry

Crossref · 10.1093/humupd/dmt061

Cites

131 of 131 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 131 references

Research works printed but not linked: 6

  1. 1985, Lancet, 2, 8469
  2. 2010, American journal of obstetrics and gynecology, 203, 201
  3. Govind, 1999, Journal of Clinical Endocrinology & Metabolism, 84, 38, 10.1210/jc.84.1.38 · DOI
  4. Loverro, 2001, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 15, 142
  5. Takahashi, 1994, Human Reproduction, 9, 2255, 10.1093/humrep/ · DOI
  6. Zaidi, 1995, Human Reproduction, 10, 1992, 10.1093/humrep/ · DOI

Cited by

Sorted by citations

Items 501–550 of 550

Related

See all

Metadata

Authors
Dewailly, D., Lujan, M. E., Carmina, E., Cedars, M. I., Laven, J., Norman, R. J., & Escobar-Morreale, H. F.
Affiliations
  • Université de Lille (FR)
  • Cornell University (US)
  • University of Palermo (IT)
  • University of California, San Francisco (US)
  • Erasmus MC (NL)
  • The University of Adelaide (AU)
  • Universidad de Alcalá (ES)
Corresponding author
Dewailly, D.
ORCID
Venue
Human Reproduction Update
Publisher
Oxford University Press (OUP)
Published
2013-12-16
Volume
20
Issue
3
Pages
334-352
ISSN
  • 1355-4786 (ISSN-L)
  • 1460-2369
DOI
10.1093/humupd/dmt061
OpenAlex
W2150346446
Cited by
551
References
131
Citations by year
2026: 25 · 2025: 47 · 2024: 51 · 2023: 52 · 2022: 53 · 2021: 26 · 2020: 43 · 2019: 56 · 2018: 39 · 2017: 39 · 2016: 47 · 2015: 39 · 2014: 28 · 2013: 1
FWCI
46.29
Type
journal article
Language
en
Open access
closed
Locations
  • Human Reproduction Update (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (acceptedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (acceptedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
  • Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
Keywords
polycystic ovary syndrome, polycystic ovary morphology, ovarian volume, antral follicle count, transvaginal ultrasound, anti-Müllerian hormone, diagnostic thresholds, ovarian morphology, ovarian stroma, ovarian blood flow, hyperandrogenism, PCOS diagnostic criteria
MeSH terms
Adolescent, Adult, Female, Ovarian Follicle, Humans, Terminology as Topic, Ovary, Polycystic Ovary Syndrome, Reproducibility of Results, Biomarkers, Anti-Mullerian Hormone, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review